Venus Remedies has added another milestone in the form of Good Manufacturing Practices (GMF) as the company has got approval from Therapeutic Goods Administration (TGA) Australia for four of its facilities - Cephalosporin, Carapenems and Oncology liquid and Oncology lyophilized.
With the grant of TGA approval, the company has once again proved that its manufacturing facilities are in-line with international regulatory standards. This development would now enable the company to export these products into Australian market. Venus has already filed dossier for meropenem which is on the verge of registration and TGA approval of facility will further expedite the process.
Besides, the company is planning to enter this market through strategic tie ups with local players, where huge market potential is forecasted for Docetaxel single vial, Gemcitabine, Topotecan, Innotecan, Imipenem cilastatin. For these four manufacturing facilities company possesses 18 international GMP certifications from different international regulatory agencies like EUGMP, INVIMA, UKRAINE, SFDA and GCC.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
